Edition:
United States

Celgene Corp (CELG.O)

CELG.O on Nasdaq

130.85USD
27 Jun 2017
Change (% chg)

$-3.00 (-2.24%)
Prev Close
$133.85
Open
$133.72
Day's High
$133.85
Day's Low
$130.78
Volume
4,481,778
Avg. Vol
3,904,970
52-wk High
$135.18
52-wk Low
$94.42

Latest Key Developments (Source: Significant Developments)

Agios Pharmaceuticals says IDHIFA NDA given PDUFA action date of Aug. 30
Tuesday, 6 Jun 2017 12:26pm EDT 

June 6 (Reuters) - Agios Pharmaceuticals Inc ::Updated data from phase 1 trial of oral IDHIFA (enasidenib) demonstrate complete responses and duration of response in patients with relapsed or refractory AML and an IDH2 mutation.Overall safety profile was consistent with previously reported data for oral IDHIFA​.IDHIFA NDA has been given a prescription drug user fee act PDUFA action date of Aug. 30, 2017.  Full Article

Celgene and Acceleron complete enrollment in MEDALIST, BELIEVE Phase 3 studies of luspatercept
Thursday, 1 Jun 2017 07:30am EDT 

June 1 (Reuters) - Celgene Corp :Celgene and Acceleron complete target enrollment in the medalist and believe Phase 3 studies of luspatercept in myelodysplastic syndromes and beta-thalassemia.Acceleron Pharma Inc - ‍companies expect to report top-line results from Phase 3 studies in mid-2018​.Acceleron Pharma Inc - ‍medalist phase 3 trial has enrolled 210 patients with lower-risk mds​.Acceleron Pharma Inc - ‍believe phase 3 trial has enrolled 300 patients with transfusion dependent beta-thalassemia​.  Full Article

Celgene on track to achieve or exceed 2020 forecast - CEO
Thursday, 27 Apr 2017 10:05am EDT 

April 27 (Reuters) - Celgene Corp :Celgene CEO says on track to achieve or exceed 2020 forecast.Celgene sees Otezla net sales rebounding, achieving full-year forecast.  Full Article

Acceleron says enrolment for late stage studies now expected to be completed in Q2
Thursday, 27 Apr 2017 07:35am EDT 

April 27 (Reuters) - Acceleron Pharma Inc :Acceleron provides clinical development updates on luspatercept program.Acceleron pharma inc says enrollment in MEDALIST and BELIEVE phase 3 studies now expected to be completed in q2 2017."we now look forward to reporting topline results from medalist and believe phase 3 studies in mid-2018".Acceleron pharma inc says acceleron and celgene also plan to initiate a third phase 3 trial of luspatercept.New phase 3 trial of luspatercept is expected to be initiated in early 2018.  Full Article

Diplomat Pharmacy on March 31,co, units, Celgene entered into pharmacy distribution, services agreement to be effective July 1, 2017
Thursday, 13 Apr 2017 08:15am EDT 

Celgene Corp : Diplomat Pharmacy Inc - on March 31,co, units, Celgene Corp entered into a pharmacy distribution and services agreement to be effective July 1, 2017 . Diplomat pharmacy - on effective date, agreement will replace co's current agreement with Celgene, as amended, which is set to expire on June 30, 2017 . Diplomat pharmacy - agreement sets forth terms and conditions on which company will purchase specialty drugs from Celgene and provide certain services .Diplomat Pharmacy - under terms services to be provided in connection with dispensing prescriptions for specialty drugs after expiration of current deal.  Full Article

Cipher Pharmaceuticals appoints Robert Tessarolo as CEO
Monday, 20 Mar 2017 04:00pm EDT 

Cipher Pharmaceuticals Inc : Cipher Pharmaceuticals appoints Robert Tessarolo as CEO . Says Tessarolo has been appointed president and chief executive officer of Cipher, effective April 17, 2017 .Cipher Pharmaceuticals Inc - Tessarolo most recently held position of vice president & general manager with Celgene Corporation.  Full Article

Agios Pharmaceuticals announces MTAP pathway research program and collaboration agreement with Celgene
Monday, 13 Mar 2017 07:30am EDT 

Agios Pharmaceuticals Inc : Agios announces MTAP pathway research program as development program and development candidate under master research and collaboration agreement with Celgene . Says Celgene will pay Agios an $8 million designation fee for MTAP pathway program . Agios Pharmaceuticals Inc - Celgene will have an opt-in right on program up through Phase 1 dose escalation for at least a $30 million fee . Agios Pharmaceuticals Inc - Agios will be eligible for up to $169 million in clinical and regulatory milestone payments .Agios Pharmaceuticals - co, Celgene to have global co-development and co-commercialization rights with worldwide 50/50 cost and profit share on MTAP pathway program.  Full Article

Juno Therapeutics reports qtrly net loss per share $0.51
Wednesday, 1 Mar 2017 04:05pm EST 

Juno Therapeutics Inc : Juno Therapeutics reports fourth quarter and 2016 financial results . Juno Therapeutics Inc - 2017 cash burn guidance of $270 million to $300 million . Juno Therapeutics Inc sees 2017 capital expenditures estimated to be between $22 million and $27 million . Juno Therapeutics Inc sees 2017 operating burn estimated to be between $245 million and $275 million . Juno Therapeutics Inc qtrly net loss per share $0.51 . Juno Therapeutics Inc qtrly revenue $21.2 million versus $ 4.2 million . Q4 earnings per share view $-0.61, revenue view $14.6 million -- Thomson Reuters I/B/E/S . Juno Therapeutics Inc qtrly net loss per share non-gaap $0.65 .Says "discontinuing development of jcar015 in r/r adult all to focus on defined cell product in this setting".  Full Article

FDA expands indication for Revlimid in multiple myeloma patients following auto-HSCT
Wednesday, 22 Feb 2017 04:02pm EST 

Celgene Corp : FDA expands indication for Revlimid® (lenalidomide) as a maintenance treatment for patients with multiple myeloma following autologous hematopoietic stem cell transplant (auto-HSCT) . Celgene Corp - FDA expanded existing indication for revlimid 10 mg capsules to include use for patients with multiple myeloma as maintenance therapy .Celgene Corp- approval was based on two large studies comparing revlimid maintenance therapy versus no maintenance.  Full Article

Celgene reports positive results from Phase III sunbeam trial of oral ozanimod in patients with relapsing multiple sclerosis
Friday, 17 Feb 2017 07:30am EST 

Celgene Corp : Celgene announces positive results from Phase III sunbeam trial of oral ozanimod in patients with relapsing multiple sclerosis . Celgene Corp - safety and tolerability consistent with phase ii studies . Celgene Corp - study met its primary endpoint in reducing annualized relapse rate (arr) and measured secondary endpoints, compared to interferon (ifn) β-1a (avonex(reg)) . Says study met its primary endpoint .Celgene corp - confirmatory Phase III radiance trial data expected in q2 of 2017.  Full Article

More From Around the Web

BRIEF-Bluebird Bio, Celgene Corp announce updated clinical results from ongoing first-in-human multicenter study

* Bluebird Bio and Celgene Corporation announce updated clinical results from ongoing first-in-human multicenter study of bb2121 anti-bcma car t cell therapy in relapsed/refractory multiple myeloma at ASCO annual meeting